Molecular Docking and Toxicity Analysis of Novel Atorvastatin Structural Analogues with HMG-CoA Reductase

This study aims to design a potent drug for cardiovascular disorders in which HMG-CoA is the main target. Analogue based Drug Design (ABDD) approach was used and six Atorvastatin analogues have been designed on the basis of their drugability, observed by an online tool ‘Osiris’. All analogues have been minimized with a commercial software Hyperchem 8.0 and then been docked against the target i.e. enzyme HMG-CoA reductase, with Gold 3.01 docking tool. Docking studies of designed analogues shows that the -CH2CH2CH3 and -Cl substituents of Atorvastatin that were designed by modification at Fluorine atom of drug molecule are showing maximum binding affinity with target. Toxicity studies results for these analogues have also been found favorable.

[1]  Harry R. Bartlett,et al.  Relationships between HMG‐CoA reductase inhibitors (statin) use and strength, balance and falls in older people , 2012, Internal medicine journal.

[2]  A. Hirayama,et al.  HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[3]  T. Kohlmann,et al.  Cholesterol, C-Reactive Protein, and Periodontitis: HMG-CoA-Reductase Inhibitors (Statins) as Effect Modifiers , 2011, ISRN dentistry.

[4]  K. Pathak,et al.  Statins therapy: a review on conventional and novel formulation approaches , 2011, The Journal of pharmacy and pharmacology.

[5]  Christos G Mihos,et al.  Pleiotropic effects of the HMG-CoA reductase inhibitors , 2011, International journal of general medicine.

[6]  P. Hydzik,et al.  [Side effects of the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by Atorvastatin therapy]. , 2011, Przeglad lekarski.

[7]  F. Hu,et al.  Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. , 2010, The American journal of clinical nutrition.

[8]  D. Yellon,et al.  Wake Up and Smell the Coffee: Yet Another No Go for Cardiac Patients? , 2008, Cardiovascular Drugs and Therapy.

[9]  V. D. da Silva,et al.  Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. , 2008, The journal of physical chemistry. A.

[10]  Claudio Napoli,et al.  Nutrition, physical activity, and cardiovascular disease: an update. , 2007, Cardiovascular research.

[11]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.